Impact of Smoking Status on Mortality in STEMI Patients Undergoing Mechanical Reperfusion for STEMI: Insights from the ISACS–STEMI COVID-19 Registry

Giuseppe De Luca 1,*, Magdy Algowhary 2*, Berat Uguz 3, Dinaldo C. Oliveira 4, Vladimir Ganyukov 5*, Zan Zimbakov 6, Mila Cercek 7, Lisette Okkels Jensen 8, Poay Huan Loh 9, Lucian Calmac 10, Gerard Roura i Ferrer 11, Alexandre Quadros 12, Marek Milewski 13*, Fortunato Scotto D’Uccio 14, Clemens von Birgelen 15, Francesco Versaci 16, Jurrien Ten Berg 17, Gianni Casella 18, Aaron Wong Sung Lung 19, Petr Kala 20, José Luis Diez Gil 21, Xavier Carrillo 22, Maurits Dirksen 23, Victor M. Becerra-Munoz 24, Michael Kang-yin Lee 25, Dafsa Arifa Juzar 26, Rodrigo de Moura Joaquim 27, Roberto Paladino 28, Davor Milicic 29, Periklis Davlouros 30, Nikola Bakranceski 31, Filippo Zilio 32, Luca Donazzan 33, Adriaan Kraaijeveld 34, Gennaro Galasso 35, Lux Arpad 36, Marinucci Lucia 37, Guiducci Vincenzo 38, Maurizio Menichelli 39, Alessandra Scoccia 40, Aylin Hatice Yamac 41, Kadir Ugur Mert 42, Xacobe Flores Rios 43, Tomas Kovarnik 44, Michal Kidawa 45, José Moreu 46, Flavien Vincent 47, Enrico Fabris 48, Inigo Lozano Martinez-Luengas 49, Marco Boccalatte 50, Francisco Bosa Ojeda 51, Carlos Arellano-Serrano 52, Gianluca Caiazzo 53, Giuseppe Cerrincone 54, Hsien-Li Kao 55, Juan Sanches Forés 56, Luigi Vignali 57, Helder Pereira 58, Stephane Manzo 59, Santiago Ordoñez 60, Alev Arat Özkan 61, Bruno Scheller 62, Heidi Lehtola 63, Rui Teles 64, Christos Mantis 65, Ylitalo Antti 66, João António Brum Silveira 67, Rodrigo Zoni 68, Ivan Bessonov 69, Stefano Savonitto 70, George Kochiadakis 71, Dimitrios Alexopulos 72, Carlos E. Uribe 73, John Kanakakis 74, Benjamin Faurie 75, Gabriele Gabrielli 76, Alejandro Gutierrez Barrios 77, Juan Pablo Bachini 78, Alex Rocha 79, Frankie Chor-Cheung Tam 80, Alfredo Rodriguez 81, Antonia Anna Lukito 82, Veauthyelau Saint-Joy 83, Gustavo Pessah 84, Andrea Tuccillo 85, Giuliana Cortese 86, Guido Parodi 86, Mohamed Abd Bourahga 87, Elvin Kedhi 88, Pablo Lamelas 89, Harry Suryapranata 89, Matteo Nardin 90 and Monica Verdoia 91

1 Division of Clinical and Experimental Cardiology, AOU Sassari, University of Sassari, 07100 Sassari, Italy
2 Division of Cardiology, Assiut University Heart Hospital, Assiut University, Assyt 71511, Egypt
3 Division of Cardiology, Bursa City Hospital, 16000 Bursa, Turkey
4 Pronto de Socorro Cardiologico “ Prof. Luis Tavares”, Centro PROCAPE, Federal University of Pernambuco, Recife 50000-000, Brazil
5 Department of Heart and Vascular Surgery, State Research Institute for Complex Issues of Cardiovascular Diseases, 650000 Kemerovo, Russia
6 University Clinic for Cardiology, Medical Faculty, Ss’ Cyril and Methodius University, 1000 Skopje, North Macedonia
7 Centre for Intensive Internal Medicine, University Medical Centre, 1000 Ljubljana, Slovenia
8 Division of Cardiology, Odense Universites Hospital, 5000 Odense, Denmark
9 Department of Cardiology, National University Hospital, Singapore 117597, Singapore
10 Clinic Emergency Hospital of Bucharest, 010001 Bucharest, Romania
11 Interventional Cardiology Unit, Heart Disease Institute, Hospital Universitari de Bellvitge, 08016 Barcelona, Spain
12 Instituto de Cardiologia do Rio Grande do Sul, Porto Alegre 90000-00, Brazil
13 Division of Cardiology, Medical University of Silezia, 40-002 Katowice, Poland
14 Division of Cardiology, Ospedale del Mare, 00156 Napoli, Italy
15 Department of Cardiology, Medisch Spectrum Twente, Thoracentrum Twente, 7541 Enschede, The Netherlands
16 Division of Cardiology, Ospedale Santa Maria Goretti Latina, 04110 Latina, Italy
17 Division of Cardiology, St Antonius Hospital, 3434 Nieuwegein, The Netherlands
18 Division of Cardiology, Ospedale Maggiore Bologna, 40100 Bologna, Italy

Citation: De Luca, G.; Algowhary, M.; Uguz, B.; Oliveira, D.C.; Ganyukov, V.; Zimbakov, Z.; Cercek, M.; Jensen, L.O.; Loh, P.H.; Calmac, L.; et al. Impact of Smoking Status on Mortality in STEMI Patients Undergoing Mechanical Reperfusion for STEMI: Insights from the ISACS–STEMI COVID-19 Registry. J. Clin. Med. 2022, 11, 6722. https://doi.org/10.3390/jcm11226722 https://www.mdpi.com/journal/jcm
Abstract: The so-called “smoking paradox,” conditioning lower mortality in smokers among STEMI patients, has seldom been addressed in the settings of modern primary PCI protocols. The ISACS–STEMI COVID-19 is a large-scale retrospective multicenter registry addressing in-hospital mortality, reperfusion, and 30-day mortality among primary PCI patients in the era of the COVID-19 pandemic. Among the 16,083 STEMI patients, 6819 (42.3%) patients were active smokers, 2099 (13.1%) previous smokers, and 7165 (44.6%) non-smokers. Despite the impaired preprocedural recanalization \((p < 0.001)\), active smokers had a significantly better postprocedural TIMI flow compared with non-smokers \((p < 0.001)\); this was confirmed after adjustment for all baseline and procedural confounders, and the propensity score. Active smokers had a significantly lower in-hospital \((p < 0.001)\) and 30-day \((p < 0.001)\) mortality compared with non-smokers and previous smokers; this was confirmed after adjustment for all baseline and procedural confounders, and the propensity score. In conclusion, in our population, active smoking was significantly associated with improved epicardial recanalization and lower in-hospital and 30-day mortality compared with previous and non-smoking history.

Keywords: myocardial infarction; smoking paradox; percutaneous coronary intervention; COVID-19

1. Introduction

Coronary artery disease still represents the leading cause of mortality in developed countries. While large attention has been paid to the identification of new risk factors [1–4], traditional risk factors, especially cigarette smoking, cannot be neglected. In fact, still approximately 30% of all deaths due to coronary artery disease (CAD) in the United States annually are attributable to smoking [5].

Several studies have been conducted, especially in the setting of ST-segment elevation myocardial infarction (STEMI), suggesting the existence of a “smokers’ paradox,” related to the more favorable outcome of smokers compared with non-smokers [6–10]. Similar findings have been observed among patients with acute ischemic stroke, acute heart failure, and cardiac arrest [11–14].

This paradoxically lower mortality observed among smokers was mainly attributed to their younger age, fewer comorbidities, lesser extent of CAD, in addition to potential pathophysiological differences between smokers and non-smokers, including a greater thrombus burden in smokers, leading to greater efficacy of thrombolytic therapy [15–17], and greater responsiveness to antiplatelet therapies [18–21]. However, primary PCI, when applied in a timely fashion, currently represents the best indicated reperfusion therapy for the treatment of STEMI. Several reports have investigated the prognostic impact of smoking
with contrasting results. In the COVID era, the increased susceptibility of smokers to respiratory disease and the enhanced thrombotic risk associated with COVID-19 infection, could influence the existence of different outcome results according to smoking status. Moreover, recent reports have clearly shown a reduction in acute coronary cases during the pandemic, presumably due to a public fear of coronavirus contagion that impacted on patient willingness to present to a hospital [22–27]. An additional observation was the prolonged time from symptom onset to treatment [28–30] that contributed to explain the higher mortality among STEMI patients observed in 2020.

Therefore, the aim of the present study was to investigate the impact of smoking status on angiographic and clinical outcome in a large cohort of patients enrolled also during the COVID-19 pandemic.

2. Materials and Methods

Our study population is represented by patients enrolled in the International Study on Acute Coronary Syndromes—ST-segment Elevation Myocardial Infarction (ISACS–STEMI) COVID-19, a large-scale retrospective multicenter registry involving primary PCI centers from Europe, Latin America, South-East Asia, and North Africa, including patients treated from the 1st of March until the 30th of June 2019 (pre-COVID period) and from the 1st of March until the 30th of June 2020 (COVID period) who underwent SARS-Cov-2 screening [31].

We collected demographic, clinical, procedural data, data on total ischemia time, door-to-balloon time, referral to primary PCI facility, PCI procedural data, in-hospital outcomes, including death, Stent Thrombosis (according to the ARC definition, [32]), and 30-day mortality. The study was approved by the Ethical Committee of AOU Maggiore della Carità, Novara (Protocol 571/CE date of approval 20/05/2020).

Statistical data analysis was performed by the use of SPSS Statistics Software 23.0 (IBM SPSS Inc., Chicago, IL, USA). Quantitative variables were described using median and interquartile range. Absolute frequencies and percentages were used for qualitative variables. ANOVA or the Mann–Whitney and chi-square test were used for continuous and categorical variables, respectively. Normal distribution of continuous variables was tested by the Kolmogorov–Smirnov test). Primary study endpoint was in-hospital mortality. Secondary study endpoints were postprocedural TIMI 3 flow and 30-day mortality. We used the propensity score technique to account for potential confounding between groups, as previously described [33,34]. For each patient, a propensity score indicating the likelihood of being active was calculated through step-forward logistic regression analysis that identified variables independently associated with active smoking. We included baseline clinical variables associated with active smoking at univariable analysis (inclusion in the model: $p < 0.05$; exclusion from the model: $p < 0.1$). The following variables were entered into the model: age, gender, diabetes, hypertension, family history of CAD, previous STEMI, previous PCI, previous CABG, type of referral, ischemia time, door-to-balloon time, anterior STEMI, out-of-hospital cardiac arrest, cardiogenic shock, rescue PCI for failed thrombolysis, in-hospital RASI therapy, COVID positivity, year of revascularization (2019 vs. 2020), radial access, in-stent thrombosis, multivessels, disease, preprocedural TIMI flow, stenting, DES, mechanical support, DAPT, and additional PCI. The stepwise selection of the variable and estimation of significant probabilities were computed by means of maximal likelihood ratio test. The $\chi^2$ value was calculated from the log of the ratio of maximal partial likelihood functions. The additional value of each category of variables added sequentially was evaluated on the basis of the increases in the overall likelihood statistic ratio. The final score was built according to the global $\chi^2$ value of the multivariate statistical model and the $\chi^2$ value of each variable. The discriminatory performance of the propensity score was assessed by the receiver operating characteristic curve method, which indicated a good accuracy of the propensity score model (area under the curve $= 0.83$) [35].

The consistency of the main results for the primary outcome of the study was investigated according to propensity score values (below and over the median).
Multivariable Cox and logistic regression analyses were performed to identify the impact of smoking on primary and secondary study endpoints after adjustment for baseline con-founding factors between the two groups. All significant variables (set at a $p$-value < 0.1) were entered in block into the model. A $p < 0.05$ was considered statistically significant. The data coordinating center was established at the Eastern Piedmont University, Novara, Italy.

3. Results

Our population is represented by 16,083 STEMI patients. A total of 6819 (42.3%) patients were active smokers, 2099 (13.1%) previous smokers, and 7165 (44.6%) non-smokers. As shown in Table 1, active smokers were nine years younger and more often males compared with non-smokers. Smokers were less often affected by diabetes ($p < 0.001$), hypertension ($p < 0.001$), and hypercholesterolemia ($p < 0.001$), with lower prevalence of previous STEMI ($p < 0.001$), previous PCI ($p < 0.001$), or CABG ($p < 0.001$), but more often had a positive family history of CAD ($p < 0.001$). Smokers had a shorter ischemia time ($p < 0.001$), less often had anterior MI ($p < 0.001$), cardiogenic shock ($p < 0.001$), and out-of-hospital cardiac arrest ($p < 0.001$), but more often rescue PCI failed after thrombolysis ($p < 0.001$). Angiographic features are displayed in Table 2. Smokers less often had multivessel disease ($p < 0.001$), in-stent thrombosis ($p < 0.001$), received less often a mechanical support ($p < 0.001$) or underwent additional PCI ($p = 0.001$), whereas they received more often a coronary stent ($p < 0.001$), a DES ($p < 0.001$) and DAPT ($p < 0.001$). Despite the impaired preprocedural recanalization ($p < 0.001$), smokers had a significantly better postprocedural TIMI flow as compared to non-smokers ($p < 0.001$) (Figure 1). A significant association was observed with the percentage of SARS-COV 2 positive patients, and less often observed among smokers. Our main results were confirmed in both pre-COVID ($p < 0.001$) and COVID era ($p < 0.001$), and in both young ($p < 0.001$) and elderly patients ($p = 0.013$) (Figures S1 and S2). The results were additionally confirmed in the analysis based on the propensity score (Figure S3). The association between active smoking and postprocedural TIMI flow was confirmed after adjustment for all confounders (age, gender, diabetes, hypertension, hypercholesterolemia, family history of CAD, previous STEMI, previous PCI, previous CABG, access by ambulance, ischemia time, door-to-balloon time, anterior MI, out-of-hospital cardiac arrest, cardiogenic shock, rescue PCI, radial access, anterior MI, infarct-related artery, in-stent thrombosis, preprocedural TIMI flow 0, use of stent and DES, mechanical support, DAPT, multivessel disease, additional PCI, year of intervention, propensity score, and COVID positivity) (OR [95% CI] = 1.18 [1.04–1.36], $p = 0.014$).

Table 1. Baseline demographic and clinical characteristics according to smoking status.

| Variable                        | Active Smokers ($n = 6819$) | Previous Smokers ($n = 2099$) | Non-Smokers ($n = 7165$) | $p$ Value |
|--------------------------------|-----------------------------|-------------------------------|--------------------------|-----------|
| Age (median, IQR)              | 58 (51–65)                  | 67 (59–75)                    | 67 (58–77)               | <0.001    |
| Age > 75 year—n (%)            | 410 (6.0)                   | 533 (25.4)                    | 2104 (29.4)              | <0.001    |
| Male gender—n (%)              | 5538 (81.2)                 | 1773 (84.5)                   | 4853 (67.7)              | <0.001    |
| Diabetes mellitus—n (%)        | 1324 (19.4)                 | 502 (23.9)                    | 1986 (27.7)              | <0.001    |
| Hypertension—n (%)             | 3252 (47.7)                 | 1280 (61.0)                   | 4281 (59.7)              | <0.001    |
| Hypercholesterolemia—n (%)     | 2579 (37.8)                 | 1033 (49.2)                   | 2741 (38.3)              | <0.001    |
| Family history of CAD—n (%)    | 1667 (24.4)                 | 495 (23.6)                    | 1136 (15.9)              | <0.001    |
| Previous STEMI—n (%)           | 571 (8.4)                   | 335 (16)                      | 637 (8.9)                | <0.001    |
| Previous PCI—n (%)             | 722 (10.6)                  | 432 (20.6)                    | 839 (11.7)               | <0.001    |
| Previous CABG—n (%)            | 57 (0.8)                    | 73 (3.5)                      | 142 (2.0)                | <0.001    |
| Referral to primary PCI hospital |                             |                               |                          |           |
Table 1. Cont.

| Variable                          | Active Smokers | Previous Smokers | Non-Smokers | p Value |
|-----------------------------------|----------------|------------------|-------------|---------|
|                                  | (n = 6819)     | (n = 2099)       | (n = 7165)  |         |
| **Type**                          |                |                  |             |         |
| Ambulance (from community)—n (%)  | 3328 (48.8)    | 1074 (51.2)      | 3336 (46.6) | <0.001  |
| Direct access—n (%)               | 1820 (26.7)    | 512 (24.4)       | 2181 (30.4) |         |
| Spoke—n (%)                       | 1671 (24.5)    | 513 (24.4)       | 1648 (23.0) |         |
| **Time delays**                   |                |                  |             |         |
| Ischemia time, median (25–75th)   |                |                  |             |         |
| Total ischemia time <6 h—n (%)    |                |                  |             | <0.001  |
| 6–12 h—n (%)                     |                |                  |             | <0.001  |
| 12–24 h—n (%)                    |                |                  |             | <0.001  |
| >24 h—n (%)                      |                |                  |             | <0.001  |
| Total ischemia time > 12 h—n (%)  |                |                  |             | <0.001  |
| Door-to-balloon time, median (25–75th) |        |                  |             | <0.001  |
| Door-to-balloon time <30 min—n (%)|                |                  |             | <0.001  |
| 30–60 min—n (%)                  |                |                  |             | <0.001  |
| >60 min—n (%)                    |                |                  |             | <0.001  |
| Door-to-balloon time > 30 min—n (%)|        |                  |             | <0.001  |
| **Clinical presentation**         |                |                  |             |         |
| Anterior STEMI—n (%)              |                |                  |             | <0.001  |
| Out-of-hospital cardiac arrest—n (%)|          |                  |             | <0.001  |
| Cardiogenic shock—n (%)           |                |                  |             | <0.001  |
| Rescue PCI for failed thrombolysis—n (%)|   |                  |             | <0.001  |
| In-hospital RASI therapy—n (%)    |                |                  |             | <0.001  |
| COVID positivity (%)              |                |                  |             | <0.001  |

A Mann–Whitney test. CAD = coronary artery disease; STEMI = ST-segment elevation myocardial infarction; PCI = percutaneous coronary intervention; CABG 0 = coronary artery bypass graft.

Table 2. Angiographic and procedural characteristics.

| Variable                          | Active Smokers | Previous Smokers | Non-Smokers | p Value |
|-----------------------------------|----------------|------------------|-------------|---------|
|                                  | (n = 6819)     | (n = 2099)       | (n = 7165)  |         |
| **Radial Access (%)**             | 5289 (77.6)    | 1698 (80.9)      | 5281 (73.7) | <0.001  |
| **Culprit vessel**                |                |                  |             |         |
| Left main—n (%)                  | 82 (1.2)       | 49 (2.3)         | 121 (1.7)   |         |
| Left anterior descending artery—n (%)| 2976 (43.6) | 852 (40.6)       | 3530 (49.3) |         |
| Circumflex—n (%)                 | 1064 (15.6)    | 362 (17.2)       | 924 (12.9)  | <0.001  |
| Right coronary artery—n (%)      | 2664 (39.1)    | 812 (38.7)       | 2525 (35.2) | <0.001  |
| Anterolateral branch—n (%)       | 12 (0.2)       | 7 (0.3)          | 22 (0.3)    |         |
| SVG n (%)                        | 20 (0.3)       | 17 (0.8)         | 42 (0.6)    |         |
| In-stent thrombosis—n (%)        | 238 (3.5)      | 127 (6.1)        | 267 (3.7)   | <0.001  |
| **Multivessel disease—n (%)**    | 3145 (46.1)    | 1062 (50.6)      | 3679 (51.3) | <0.001  |
| Preprocedural TIMI 0 flow—n (%)  | 4632 (67.9)    | 1353 (64.5)      | 4746 (66.2) | 0.007   |
| Thrombectomy—n (%)               | 1112 (16.3)    | 342 (16.3)       | 1109 (15.5) | 0.36    |
| Stenting—n (%)                   | 6391 (93.7)    | 1929 (91.9)      | 6447 (90)   | <0.001  |
| Drug-eluting stent—n (%)         | 6150 (90.2)    | 1858 (88.5)      | 6246 (87.2) | <0.001  |
| Postprocedural TIMI 3 flow—n (%) | 6402 (93.9)    | 1958 (93.3)      | 6461 (90.2) | <0.001  |
| Gp IIb-IIIa inhibitors/cangrelor—n (%)| 1404 (20.6) | 441 (21.0)       | 1422 (19.8) | 0.38    |
| Bivalirudin—n (%)                | 18 (0.3)       | 9 (0.4)          | 25 (0.3)    | 0.44    |
| Mechanical support—n (%)         | 164 (2.4)      | 68 (3.2)         | 265 (3.7)   | <0.001  |
| Additional PCI                   |                |                  |             |         |
| During the index procedure—n (%) | 627 (9.2)      | 260 (12.4)       | 689 (9.6)   | <0.001  |
| Staged—n (%)                     | 716 (10.5)     | 223 (10.6)       | 747 (10.4)  | 0.001   |
| DAPT therapy—n (%)               | 6769 (99.3)    | 2071 (98.7)      | 7065 (98.6) | <0.001  |

TIMI = thrombolysis in myocardial infarction; DAPT = dual antiplatelet therapy; RASI: renin-angiotensin system inhibitors.
Smokers had a significantly lower in-hospital (Figure 2) and 30-day (Figure 3) mortality compared with non-smokers and previous smokers; this was confirmed in both pre-COVID ($p < 0.001$) and COVID era ($p < 0.001$) and in young ($p < 0.001$) and older patients ($p < 0.001$) (Figures S4, S5, S7 and S8). The results were additionally confirmed in the analysis based on the propensity score (Figures S6 and S9). The association between active smoking and better survival was confirmed at multivariate analysis after adjustment for all confounders (age, gender, diabetes, hypertension, hypercholesterolemia, family history of CAD, previous STEMI, previous PCI, previous CABG, access by ambulance, ischemia time, door-to-balloon time, anterior MI, out-of-hospital cardiac arrest, cardiogenic shock, rescue PCI, radial access, anterior MI, infarct-related artery, in-stent thrombosis, preprocedural TIMI flow 0, use of stent and DES, mechanical support, DAPT, multivessel disease, additional PCI, year of intervention, propensity score, and COVID positivity) (in-hospital death: OR [95% CI] = 0.75 [0.62–0.9], $p = 0.003$; 30-day death: HR [95% CI] = 0.74 [0.64–0.86], $p < 0.0001$).

![Figure 1](image1.png)

**Figure 1.** Bar graphs show the association between smoking status and postprocedural TIMI flow.

![Figure 2](image2.png)

**Figure 2.** Bar graphs show the association between smoking status and in-hospital mortality.

![Figure 3](image3.png)

**Figure 3.** Kaplan–Meier survival curves of STEMI patients according to smoking status.
Figure 2. Bar graphs show the association between smoking status and in-hospital mortality.

Figure 3. Kaplan–Meier survival curves of STEMI patients according to smoking status.

4. Discussion

Our study is one of the largest reports on the association between smoking status and mortality in STEMI patients undergoing primary angioplasty, especially during the COVID pandemic. We found that active smokers had significantly better epicardial reperfusion and both in-hospital and 30-day survival compared with previous smokers and non-smokers. The association persisted even after correction for all baseline confounders, including the year of intervention, COVID positivity, and the propensity score.

Cigarette smoking is a well-known risk factor for coronary artery disease [5,36]. In fact, smokers were younger than non-smokers and were less likely to have additional established risk factors than non-smokers, suggesting the deleterious effect of smoking as a cause of myocardial infarction. However, despite the adjustment for all these confounders, smoking was still associated with a reduced mortality. While we cannot certainly exclude masked unmeasured confounders, it is possible that underlying biological differences in pathophysiology and response to the treatment in smokers versus non-smokers with STEMI could also have accounted, at least in part, for this paradoxical association.

Several studies conducted with thrombolysis have shown that smoking was associated with a lower mortality at both short- and long-term follow up [37–39]. Although, in most of these studies, the association between smoking and reduced mortality disappeared after correction for multiple confounders, some other studies observed a persistently lower mortality, even after adjustment. One of the explanations is the fact the smoking does not affect atherosclerotic plaque vulnerability, whereas it induces a hypercoagulation and pro-thrombotic state by endothelial dysfunction, increased platelet activation and aggregation, increased circulating levels of fibrinogen, and increased thrombin generation [40,41]. It has been shown, indeed, that components of cigarette smoke impair fibrin crosslinking [42]. Therefore, smoking may be predominantly thrombogenic and less likely atherogenic, making these patients more amenable for thrombolytic therapy and able to obtain more benefits from antiplatelet therapies. In fact, among patients reperfused with thrombolysis, smoking is associated with better epicardial [38] and myocardial reperfusion [43] compared with non-smokers.

Several studies have recently investigated the smoking paradox among patients undergoing mechanical reperfusion, with conflicting results. Redfors et al. [44] reported the prognostic impact of smoking among patients enrolled in CADILLAC trial. The authors observed a significantly lower mortality at 30-day and 1-year follow up in smokers com-
pared with non-smokers. However, the difference disappeared after adjustment for all confounding factors. In another study by Steele et al. [45] including 3133 STEMI patients undergoing mechanical reperfusion, smoking was associated with a significantly increased mortality (hazard ratio 1.35 (95% CI 1.04–1.74)) compared with never smokers at 3 years after adjustment for differences in baseline variables. The risk for ex-smokers (hazard ratio 0.99 (0.76–1.28)) was similar to never smokers.

Opposite findings have been observed in the largest study so far conducted in primary PCI. Gupta et al., including more than 900,000 STEMI patients [46], found that smoking was associated with a significantly lower mortality, even after the adjustment for all baseline confounders. However, the mortality difference between smokers and non-smokers diminished substantially with increasing age and was no longer significant in nonagenarians with STEMI. These data suggest that the overall association of smoking with lower in-hospital mortality is driven mostly by younger age groups. However, given the lack of angiographic data, the authors were unable to account for the severity of CAD or to assess the procedural success of PCI. Another limitation is the very short-term follow up.

The present study is one of the largest on primary PCI, including more than 16,000 STEMI patients, and the first study conducted in the COVID era. In fact, the COVID-19 pandemic has been shown to increase mortality among STEMI patients by both direct and indirect effects, including a longer delay to presentation. We found that active smoking was associated with a significantly improved epicardial reperfusion (TIMI 3), especially as compared with non-smokers. Furthermore, active smokers had a significantly lower mortality as compared with non-smokers and previous smokers. Our results were confirmed in the sub analysis according to the year of intervention (COVID and pre-COVID era), age (older and younger than 75 years of age), and in patients with low or high propensity score values (below or upper the median value). The association between active smoking and angiographic and clinical outcome was confirmed after multivariate adjustment for all confounders, including the year of intervention and the propensity score.

A possible biological mechanism may explain that the paradoxically lower mortality among smokers treated by primary PCI is the potential different pathophysiology underlying the onset of infarction, mainly related among smokers to hypercoagulation and prothrombotic state by endothelial dysfunction, increased platelet activation and aggregation, increased circulating levels of fibrinogen, and increased thrombin generation [40,41], rather than atherosclerotic plaque vulnerability. This may also condition the response to several antithrombotic therapies.

In fact, a sub analysis of the HORIZONS-AMI trial also showed that, among STEMI patients undergoing pPCI for STEMI, bivalirudin monotherapy was associated with lower 30-day and 1-year mortality compared with unfractionated heparin plus glycoprotein IIb/IIIa inhibitors in smokers but not in non-smokers [47]. Furthermore, it has been suggested that smoking could affect responsiveness to antiplatelet therapies, mainly ADP antagonists. A sub analysis of the CLARITY-TIMI 28 trial, showed that clopidogrel reduced the rate of the primary end point (combined rates of occluded infarct-related artery or death and MI before angiography), especially among patients who smoked ≥10 cigarettes per day versus those who did not [48]. Similarly, in the CHARISMA trial clopidogrel reduced all-cause and cardiovascular mortality at 28 months in current smokers but not in non-smokers [19]. Similar impacts of smoking on the benefits from clopidogrel has been reported in other studies [18]. Pharmacokinetic and pharmacodynamics studies demonstrated that among patients treated with clopidogrel, smoking was associated with a greater inhibition of platelet aggregation, lower P2Y12 reaction units, and showed high platelet reactivity less often [20]. The induction of cytochrome P450 1A2 and 2B6 enzymes by cigarette smoking, both of which are involved in the hepatic biotransformation of clopidogrel to its active metabolite [49] has been identified as a possible explanation of the different response to clopidogrel between smokers versus nonsmokers. Additional studies have been conducted on prasugrel, suggesting a similar effect of smoking status. A platelet-function sub study of the TRILOGY-ACS trial [21]
showed that, among medically managed ACS patients randomly assigned to prasugrel or clopidogrel, smokers had lower P2Y12 reaction unit values at 6 months in both treatment groups compared with non-smokers. It has been demonstrated that nicotine is associated with higher P2Y12 receptor expression in human platelet lysates; this, therefore, could explain the observed effect of smoking on platelet inhibition [50]. These findings can contribute to understanding the observed significant reduction of ischemic outcomes with prasugrel versus clopidogrel among smokers [21].

These data on the differential clinical efficacy of antithrombotic therapies in smokers versus non-smokers could be a possible mechanistic explanation for the association of smoking with lower in-hospital mortality in patients undergoing pPCI for STEMI.

It must be emphasized that our findings and the overall concept of the smoking paradox should not erroneously interpreted as the beneficial effects from cigarette smoking. In fact, the lower prevalence of conventional risk factors among active smokers indirectly support the promotion of atherothrombosis, by active smoking, that led to STEMI at a younger age. The harmful effects of smoking have been largely proven, and these modest differences in short-term survival would likely be offset by the long-term mortality attributable to cigarette smoking. Therefore, all efforts should be carried out to strongly promote smoking cessation as a public health measure to reduce the burden of cardiovascular disease and its related mortality.

Study Limitations

This study is limited by its retrospective design. It was conducted during a pandemic emergency, which was challenging and expected to encounter missing data. Cumulative smoking exposure in terms of number of pack years could not be quantified, and we were unable to study the association of the amount of smoking with outcomes. We were also unable to determine the time of smoking cessation for former smokers and neither did we assess infarct size. Moreover, even after statistical correction, the large differences in some strong prognostically relevant variables, particularly much younger age, do not allow for us to exclude that smoking is mostly a marker of STEMI at a younger age, where this risk factor is largely predominant as a direct prothrombotic cause of coronary occlusion. Therefore, the large differences in prognostically relevant baseline characteristics suggest prudence with regard to causal conclusions.

5. Conclusions

Our study showed that smoking is independently associated with improved epicardial re-canalization and lower in-hospital and 30-day mortality as compared with both previous smokers and non-smokers.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/jcm11226722/s1, Figure S1. Bar Graphs show the association between smoking status and postprocedural TIMI 3 flow in patients treated in 2019 (precovid era, left graph) and 2020 (covid era, right graph). Figure S2. Bar Graphs show the association between smoking status and postprocedural TIMI 3 flow in young (left graph) and older (right graph) patients. Figure S3. Bar Graphs show the association between smoking status and postprocedural TIMI 3 flow in in patients with low (left graph) and high (right graph) propensity score. Figure S4. Bar Graphs show the association between smoking status and in-hospital mortality in patients treated in 2019 (precovid era, left graph) and 2020 (covid era, right graph). Figure S5. Bar Graphs show the association between smoking status and in-hospital mortality in young (left graph) and older (right graph) patients. Figure S6. Bar Graphs show the association between smoking status and in-hospital mortality in patients with low (right graph) and high (left graph) propensity score. Figure S7. Kaplan-Meier survival curves according to smoking status in patients treated in 2019 (left graph) and 2020 (right graph). Figure S8. Kaplan-Meier survival curves according to smoking status in young (left graph) and older (right graph) patients. Figure S9. Kaplan-Meier survival curves according to smoking status in patients with low (left graph) and high (right graph) propensity score.
Author Contributions: All the authors contributed to data collection and final approval of the manuscript; G.D.L., G.C. (Gianni Casella) and M.V. performed the data analysis. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethical Committee of AOU Maggiore della Carità, Novara (protocol code Novara 571/CE).

Informed Consent Statement: Informed consent was not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Verdoia, M.; Barbieri, L.; Di Giovinle, G.; Marino, P.; Suryapranata, H.; De Luca, G.; Novara Atherosclerosis Study Group (NAS). Neutrophil to Lymphocyte Ratio and the Extent of Coronary Artery Disease: Results From a Large Cohort Study. *Angiology* 2016, 67, 75–82. [CrossRef] [PubMed]
2. De Luca, G.; Verdoia, M.; Cassetti, E.; Schaffer, A.; Cavallino, C.; Bolzani, V.; Marino, P.; Novara Atherosclerosis Study Group (NAS). High fibrinogen level is an independent predictor of presence and extent of coronary artery disease among Italian population. *J. Thromb. Thrombolysis* 2011, 31, 458–463. [CrossRef] [PubMed]
3. Verdoia, M.; Schaffer, A.; Sartori, C.; Barbieri, L.; Cassetti, E.; Marino, P.; Galasso, G.; De Luca, G. Vitamin D deficiency is independently associated with the extent of coronary artery disease. *Eur. J. Clin. Investig.* 2014, 44, 634–642. [CrossRef] [PubMed]
4. Barbieri, L.; Verdoia, M.; Schaffer, A.; Marino, P.; Suryapranata, H.; De Luca, G.; Novara Atherosclerosis Study Group (NAS). Impact of sex on uric acid levels and its relationship with the extent of coronary artery disease: A single-centre study. *Atherosclerosis* 2015, 241, 241–248. [CrossRef] [PubMed]
5. Ockene, I.S.; Miller, N.H. Cigarette smoking, cardiovascular disease, and stroke: A statement for healthcare professionals from the American Heart Association. *American Heart Association Task Force on Risk Reduction*. *Circulation* 1997, 96, 3243–3247. [CrossRef]
6. Barbash, G.I.; White, H.D.; Modan, M.; Diaz, R.; Hampton, J.R.; Heikkila, J.; Kristinsson, A.; Moulopoulos, S.; Paolasso, E.A.; Van der Werf, T. Significance of smoking in patients receiving thrombolytic therapy for acute myocardial infarction. Experience gleaned from the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. *Circulation* 1993, 87, 53–58. [CrossRef]
7. Helmers, C. Short and long-term prognostic indices in acute myocardial infarction. A study of 606 patients initially treated in a coronary care unit. *Acta Med. Scand. Suppl.* 1973, 555, 7–26.
8. Kelly, T.L.; Gilpin, E.; Ahnve, S.; Henning, H.; Ross, J. Smoking status at the time of acute myocardial infarction and subsequent prognosis. *Am. Heart J.* 1985, 110, 535–541.
9. Sparrow, D.; Dawber, T.R. The influence of cigarette smoking on prognosis after a first myocardial infarction. A report from the Framingham Study. *J. Chronic Dis.* 1978, 31, 425–432. [CrossRef]
10. Jaatun, H.J.; Sutradhar, S.C.; Dickstein, K. Comparison of mortality rates after acute myocar-dial infarction in smokers vs. nonsmokers. *Am. J. Cardiol.* 2004, 94, 632–636, A639. [CrossRef]
11. Ali, S.F.; Smith, E.E.; Bhatt, D.L.; Fonarow, G.C.; Schwamm, L.H. Paradoxical association of smoking in patients admitted with acute ischemic stroke. *J. Am. Heart Assoc.* 2013, 2, e000171. [CrossRef] [PubMed]
12. Fonarow, G.C.; Abraham, W.T.; Albert, N.M.; Stough, W.G.; Gheorghiade, M.; Greenberg, B.H.; O’Connor, C.M.; Nunez, E.; Yancy, C.W.; Young, J.B. A smoker’s paradox in patients hospitalized for heart failure: Findings from OPTIMIZE-HF. *Eur. Heart J.* 2008, 29, 1983–1991. [CrossRef] [PubMed]
13. Gupta, T.; Kolte, D.; Khera, S.; Aronow, W.S.; Palaniswamy, C.; Mujib, M.; Jain, D.; Sule, S.; Ahmed, A.; Iwai, S.; et al. Relation of smoking status to outcomes after cardiopulmonary resuscitation in in-hospital cardiac arrest. *Am. J. Cardiol.* 2014, 114, 169–174. [CrossRef] [PubMed]
14. Ali, S.F.; Smith, E.E.; Reeves, M.J.; Zhao, X.; Xian, Y.; Hernandez, A.F.; Bhatt, D.L.; Fonarow, G.C.; Schwamm, L.H. Smoking paradox in patients hospitalized with coronary artery disease or acute ischemic stroke: Findings from Get with The Guidelines. *Circ. Cardiovasc. Qual. Outcomes* 2015, 8, 573–580. [CrossRef] [PubMed]
15. Zahger, D.; Cerkez, B.; Cannon, C.P.; Jordan, M.; Davis, V.; Braunwald, E.; Shah, P.K. How do smokers differ from nonsmokers in their response to thrombolysis? (the TIMI-4 trial). *Am. J. Cardiol.* 1995, 75, 232–236. [CrossRef]
16. Lundergan, C.F.; Reiner, J.S.; McCarthy, W.F.; Coyne, K.S.; Califf, R.M.; Ross, A.M. Clinical predictors of early infarct-related artery patency following thrombolytic therapy: Importance of body weight, smoking history, infarct-related artery and choice of thrombolytic regimen: The GUSTO-I experience. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. *J. Am. Coll. Cardiol.* 1998, 32, 641–647.
17. de Chillou, C.; Riff, P.; Sadoul, N.; Etchevelet, G.; Feldmann, L.; Isaaz, K.; Simon, J.P.; Boursier, M.; Khalife, K.; Thissee, J.Y.; et al. Influence of cigarette smoking on rate of reopening of the infarct-related coronary artery after myocardial infarction: A multivariate analysis. *J. Am. Coll. Cardiol.* 1996, 27, 1662–1668. [CrossRef]
39. Gottlieb, S.; Boyko, V.; Zahger, D.; Balkin, J.; Hod, H.; Pelled, B.; Stern, S.; Behar, S. Smoking and prognosis after acute myocardial infarction in the thrombolytic era (Israeli Thrombolytic National Survey). J. Am. Coll. Cardiol. 1996, 28, 1506–1513. [CrossRef]
40. McGill, H.C. The cardiovascular pathology of smoking. Am. Heart J. 1988, 115, 250–257. [CrossRef]
41. Sambola, A.; Osende, J.; Hathcock, J.; Degen, M.; Nemerson, Y.; Fuster, V.; Crandall, J.; Badimon, J.J. Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation 2003, 107, 973–977. [CrossRef] [PubMed]
42. Galanakis, D.K.; Laurent, P.; Janoff, A. Cigarette smoke contains anticoagulants against fibrin aggregation and factor XIIIa in plasma. Science 1982, 217, 642–645. [CrossRef] [PubMed]
43. Galanakis, D.K.; Laurent, P.; Janoff, A. Cigarette smoke contains anticoagulants against fibrin aggregation and factor XIIIa in plasma. Science 1982, 217, 642–645. [CrossRef] [PubMed]
44. Kirtane, A.J.; Martinezclark, P.; Rahman, A.M.; Ray, K.K.; Karmapaliotis, D.; Murphy, S.A.; Giugliano, R.P.; Cannon, C.P.; Antman, E.M.; Roe, M.T.; et al. Association of smoking with improved myocardial perfusion and the angiographic characterization of myocardial tissue perfusion after fibrinolytic therapy for ST-segment elevation myocardial infarction. J. Am. Coll. Cardiol. 2005, 45, 321–323. [CrossRef] [PubMed]
45. Redfors, B.; Furer, A.; Selker, H.P.; Thiele, H.; Patel, M.R.; Chen, S.; Udelson, J.E.; Ohman, E.M.; Eitel, I.; Granger, C.B.; et al. Effect of Smoking on Outcomes of Primary PCI in Patients With STEMI. J. Am. Coll. Cardiol. 2020, 75, 1743–1754. [CrossRef]
46. Steele, L.; Palmer, J.; Lloyd, A.; Fotheringham, J.; Iqbal, J.; Grech, E.D. The impact of smoking on mortality after acute ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: A retrospective cohort outcome study at 3 years. J. Thromb. Thrombolysis 2019, 47, 520–526. [CrossRef]
47. Gupta, T.; Kolte, D.; Khera, S.; Harikrishnan, P.; Mujib, M.; Aronow, W.S.; Jain, D.; Ahmed, A.; Cooper, H.A.; Frishman, W.H.; et al. Smoker’s Paradox in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. J. Am. Heart Assoc. 2016, 5, e003370. [CrossRef]
48. Desai, N.R.; Mega, J.L.; Jiang, S.; Cannon, C.P.; Sabatine, M.S. Interaction between cigarette smoking and clinical benefit of clopidogrel. J. Am. Coll. Cardiol. 2009, 53, 1273–1278. [CrossRef]
49. Yousef, A.M.; Arafat, T.; Bulatova, N.R.; Al-Zumyli, R. Smoking behaviour modulates pharmacokinetics of orally administered clopidogrel. J. Clin. Pharm. Ther. 2008, 33, 439–449. [CrossRef]
50. Shanker, G.; Kontos, J.L.; Eckman, D.M.; Wesley-Farrington, D.; Sane, D.C. Nicotine up-regulates the expression of P2Y12 on vascular cells and megakaryoblasts. J. Thromb. Thrombolysis 2006, 22, 213–220. [CrossRef]